Opinion|Videos|July 18, 2024
NCCN Guidelines Revisions and ASCO 2024 Research Outlook
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series
- How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
- What data, results, or insights are you looking forward to coming out of ASCO 2024?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Semaglutide More Than Doubled Likelihood of MASH Resolution
2
Once-Daily Pill Zasocitinib Clears Psoriasis at Toughest Sites
3
Wildfire Smoke Raises Asthma Risks as Fires Worsen Air Quality Across North America
4
Why Cutting Trial Red Tape Won't Fix Clinical Trial Design
5